BACKGROUND:Many elderly female residents of long-term care facilities have osteoporosis and could benefit from intervention to increase bone density. OBJECTIVE: To examine the efficacy and safety of alendronate for treatment of osteoporosis in elderly female residents of long-term care facilities. DESIGN: Multicenter, randomized, double-blind, placebo-controlled 2-year study. SETTING: 25 long-term care facilities. PATIENTS: 327 elderly women with osteoporosis. INTERVENTION: Patients were randomly assigned to receive alendronate, 10 mg/d, or placebo. All patients also received vitamin D, 400 IU/d, and some patients received supplemental calcium (total intake, approximately 1500 mg/d). MEASUREMENTS: Bone mineral density (BMD) of the spine and hip and biochemical markers of bone turnover. RESULTS:Alendronate produced significantly greater increases in BMD than did placebo (24-month differences: spine, 4.4% [95% CI, 3.3% to 5.5%]; femoral neck, 3.4% [CI, 2.3% to 4.4%]). Alendronate produced greater decreases from baseline in biochemical markers of bone turnover than did placebo (P < 0.001). CONCLUSION:Alendronate increased BMD at both the spine and hip in elderly female residents of long-term care facilities.
RCT Entities:
BACKGROUND: Many elderly female residents of long-term care facilities have osteoporosis and could benefit from intervention to increase bone density. OBJECTIVE: To examine the efficacy and safety of alendronate for treatment of osteoporosis in elderly female residents of long-term care facilities. DESIGN: Multicenter, randomized, double-blind, placebo-controlled 2-year study. SETTING: 25 long-term care facilities. PATIENTS: 327 elderly women with osteoporosis. INTERVENTION: Patients were randomly assigned to receive alendronate, 10 mg/d, or placebo. All patients also received vitamin D, 400 IU/d, and some patients received supplemental calcium (total intake, approximately 1500 mg/d). MEASUREMENTS: Bone mineral density (BMD) of the spine and hip and biochemical markers of bone turnover. RESULTS:Alendronate produced significantly greater increases in BMD than did placebo (24-month differences: spine, 4.4% [95% CI, 3.3% to 5.5%]; femoral neck, 3.4% [CI, 2.3% to 4.4%]). Alendronate produced greater decreases from baseline in biochemical markers of bone turnover than did placebo (P < 0.001). CONCLUSION:Alendronate increased BMD at both the spine and hip in elderly female residents of long-term care facilities.
Authors: Cathleen S Colón-Emeric; Kenneth W Lyles; Paul House; Deborah A Levine; Anna P Schenck; Jeroan Allison; Joel Gorospe; Mary Fermazin; Kristi Oliver; Jeffrey R Curtis; Norman Weissman; Aiyuan Xie; Kenneth G Saag Journal: Am J Med Date: 2007-10 Impact factor: 4.965
Authors: Andrew R Zullo; Tingting Zhang; Yoojin Lee; Kevin W McConeghy; Lori A Daiello; Douglas P Kiel; Vincent Mor; Sarah D Berry Journal: J Am Geriatr Soc Date: 2018-12-21 Impact factor: 5.562
Authors: Sarah D Berry; Andrew R Zullo; Yoojin Lee; Vincent Mor; Kevin W McConeghy; Geetanjoli Banerjee; Ralph B D'Agostino; Lori Daiello; David Dosa; Douglas P Kiel Journal: J Gerontol A Biol Sci Med Sci Date: 2018-05-09 Impact factor: 6.053
Authors: Anna M Sawka; Nofisat Ismaila; Ann Cranney; Lehana Thabane; Monika Kastner; Amiram Gafni; Linda J Woodhouse; Richard Crilly; Angela M Cheung; Jonathan D Adachi; Robert G Josse; Alexandra Papaioannou Journal: PLoS One Date: 2010-03-03 Impact factor: 3.240
Authors: Socrates E Papapoulos; Sara A Quandt; Uri A Liberman; Marc C Hochberg; Desmond E Thompson Journal: Osteoporos Int Date: 2004-09-21 Impact factor: 4.507
Authors: Arthur N Lau; George Ioannidis; Yelena Potts; Lora M Giangregorio; Mary-Lou Van der Horst; Jonathan D Adachi; Alexandra Papaioannou Journal: BMC Geriatr Date: 2010-10-08 Impact factor: 3.921